Advertisement

The role of interleukin-2 in the treatment of cancer patients

  • John¬†Wagstaff

Table of contents

  1. Front Matter
    Pages i-x
  2. John Wagstaff
    Pages 1-5
  3. Lorenz M. Jost, Rolf A. Stahel
    Pages 7-28
  4. Sylvie Negrier, Thierry O. Philip
    Pages 29-43
  5. Giorgio Parmiani, Carlo Gambacorti-Passerini
    Pages 71-83
  6. Cornelis J. M. Melief, W. Martin Kast
    Pages 85-94
  7. Albert Von Rohr, Nick Thatcher
    Pages 95-121
  8. Reinder L. H. Bolhuis, Gerrit Stoter
    Pages 123-140
  9. Jens Atzpodien, Axel Schomburg, Hartmut Kirchner, Hubert Poliwoda
    Pages 141-167
  10. Christopher R. Franks, Peter A. Palmer
    Pages 169-185
  11. Back Matter
    Pages 187-191

About this book

Introduction

Recombinant human interleukin-2 became available for clinical use in the mid 1980s. Recent years have seen an enormous amount of clinical research with this cytokine and interleukin-2 has now been registered for use in a number of European countries for the treatment of metastatic renal cell carcinoma. This book is designed to provide the clinical oncologist wishing to use interleukin-2 with a basic background concerning the biology of the agent, a discussion concerning practical aspects, of its clinical use including management of toxicity and an overview of the clinical results together with a description of how this internesting cytokine might be developed in the future.

Keywords

carcinoma cell cytokine cytokines lymphocytes renal cell carcinoma tumor

Editors and affiliations

  • John¬†Wagstaff
    • 1
  1. 1.Department of OncologyFree University HospitalAmsterdamThe Netherlands

Bibliographic information